Business
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results
Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9
About this update from Cerus Corporation
[{"type":"text","content":"\nStrong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets\n\nTotal Revenue of $50.1 Million Grew 49% in the Fourth Quarter\n\nProduct Revenue of $39.9 Million Grew 41% in the Fourth Quarter\n\nReiterating Full-Year 2022 Product Revenue Guidance Range of $157-$164 Million\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021.\n\nRecent developments and highlights include:\n\n\nFourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the prior year period. For the full year, 2021 total revenue was $159.5 million, reflecting a 40% increase over the prior year period. Total revenue was composed of (in thousands, except %):\n\n\n\n\n \n\n\n\n \n\n\n\nThree Months Ended\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nTwelve Months Ended\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\nDecember 31,\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nDecember 31,\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2020\n\n\n\n \n\n\n\nChange\n\n\n\n \n\n\n\n2021\n\n\n\n\n2020\n\n\n\n\nChange\n\n\n\n\n\nProduct revenue\n\n\n\n \n\n\n\n$\n\n\n\n39,865\n\n\n\n \n\n\n\n$\n\n\n\n28,199\n\n\n\n \n\n\n\n41%\n\n\n\n \n\n\n\n$\n\n\n\n130,859\n\n\n\n\n$\n\n\n\n91,920\n\n\n\n\n42%\n\n\n\n\n\nGovernment contract revenue\n\n\n\n \n\n\n\n \n\n\n\n10,223\n\n\n\n \n\n\n\n \n\n\n\n5,391\n\n\n\n \n\n\n\n90%\n\n\n\n \n\n\n\n \n\n\n\n28,659\n\n\n\n\n \n\n\n\n22,329\n\n\n\n\n28%\n\n\n\n\n\nTotal revenue\n\n\n\n \n\n\n\n$\n\n\n\n50,088\n\n\n\n \n\n\n\n$\n\n\n\n33,590\n\n\n\n \n\n\n\n49%\n\n\n\n \n\n\n\n$\n\n\n\n159,518\n\n\n\n\n$\n\n\n\n114,249\n\n\n\n\n40%\n\n\n\n\n\nAs of the date of this release, the Company is reiterating its 2022 annual product revenue guidance range of $157 million to $164 million, representing a 20% to 25% increase over full-year 2021 reported product revenue.\n\n\nThis year, Cerus Corporation celebrates its 30th anniversary. Since its foundation, Cerus has recognized the critical unmet need to protect the world’s blood supply. With the INTERCEPT Blood System, Cerus hopes to continue to deliver innovative solutions in support of making safe blood products accessible globally.\n\n\nTwo of the Company’s blood center production partners, Gulf Coast Regional Blood Center and Central California Blood Center (CCBC), have ...